Adamis Pharmaceuticals (ADMP) Receiving Somewhat Favorable Media Coverage, Analysis Finds

Press coverage about Adamis Pharmaceuticals (NASDAQ:ADMP) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.4702186407831 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

A number of analysts have recently weighed in on the company. Zacks Investment Research cut Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 16th. Maxim Group set a $5.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 23rd. Raymond James Financial set a $7.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 23rd. Finally, B. Riley raised their price objective on Adamis Pharmaceuticals from $6.25 to $7.50 and gave the stock a “buy” rating in a research report on Friday, March 23rd. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $6.50.

ADMP traded up $0.03 on Friday, reaching $3.45. 260,572 shares of the stock were exchanged, compared to its average volume of 574,935. Adamis Pharmaceuticals has a fifty-two week low of $2.35 and a fifty-two week high of $6.45. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.24 and a current ratio of 2.44. The stock has a market cap of $115.19, a P/E ratio of -3.83 and a beta of 0.32.

WARNING: “Adamis Pharmaceuticals (ADMP) Receiving Somewhat Favorable Media Coverage, Analysis Finds” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3341653/adamis-pharmaceuticals-admp-receiving-somewhat-favorable-media-coverage-analysis-finds.html.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Insider Buying and Selling by Quarter for Adamis Pharmaceuticals (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

FUNCoin  Price Tops $0.0177 on Exchanges
FUNCoin Price Tops $0.0177 on Exchanges
Comparing Haynes International  & Gerdau
Comparing Haynes International & Gerdau
Civeo  to Release Quarterly Earnings on Friday
Civeo to Release Quarterly Earnings on Friday
Beneficial Bancorp  Releases  Earnings Results, Hits Estimates
Beneficial Bancorp Releases Earnings Results, Hits Estimates
Contrasting Post  & General Mills
Contrasting Post & General Mills
Critical Analysis: Biocept  and Its Competitors
Critical Analysis: Biocept and Its Competitors


Leave a Reply

© 2006-2018 Ticker Report. Google+.